Search Results for: "amgen v hospira"

Amgen v. Hospira: FEDERAL CIRCUIT ORAL ARGUMENT HELD

On April 3, 2017, the Federal Circuit heard oral argument concerning the discovery dispute between Amgen and Hospira in their litigation concerning Hospira’s proposed biosimilar of Amgen’s product Epogen®/ Procrit® (epoetin alfa) (audio available here).  In this dispute, Amgen is seeking to compel production of information concerning Hospira’s manufacturing process, including…

Read More

Upcoming Oral Arguments in BPCIA Litigation

On Friday, the United States Supreme Court set oral arguments in Amgen v. Sandoz for April 26, 2017. Today, the United States Court of Appeals for the Federal Circuit announced that oral arguments in Amgen v. Hospira will be held on April 3, 2017. Stay tuned to Big Molecule Watch for further updates.  For…

Read More

Amgen v. Hospira (epoetin alfa): District Court Lets in New Infringement Theories, Not New Defendants

As we previously reported, Amgen has sought to amend its complaint regarding Hospira’s planned epoetin alfa biosimilar to add three new defendants and two theories of infringement.  On October 3, 2016, Judge Andrews granted-in-part and denied-in-part Amgen’s motion.  First, the court denied Amgen’s request to add three defendants because “[i]t would be unreasonable to…

Read More

Litigation Update: Amgen v. Hospira (epoetin alfa)

A couple of updates on Amgen v. Hospira (epoetin alfa): Amgen has requested that the district court (D. Del., J. Andrews) grant it leave to file a second amended complaint “to add three additional defendants” who, Amgen alleges, “have directly or indirectly infringed Amgen’s patent-in-suit, United States Patent No. 5,756,349.” Meanwhile, Hospira…

Read More